This study will consist of two treatment arms (Groups A and B).~Participants will be randomised in a 1:1 ratio to one of the two treatment groups:~Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously.~Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel.
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.